The assessment of anti-GP2 autoantibodies, in particular in combination with other IBD-specific markers such as the already established antibodies to Saccharomyces cerevisiae (ASCA) [39, 40], can be a powerful serological tool to discriminate the two main clinical entities of IBD, CD, and UC [41]. The gene discussed is GP2; the disease is inflammatory bowel disease.